You have 0 items in your cart
The next generation of metabolic research is expanding well beyond conventional GLP-1 receptor agonists.
One of the most interesting emerging compounds is zenagamtide, previously known during development as amycretin.
Unlike approaches focused exclusively on GLP-1, zenagamtide is designed to combine GLP-1 receptor agonism with amylin receptor agonism in a single molecule.
That makes it an important example of the growing scientific interest in multi-pathway metabolic research.
So what exactly is zenagamtide, how does it differ from compounds such as semaglutide, cagrilintide and retatrutide, and why are researchers interested in it?
What Is Zenagamtide?
Zenagamtide is an investigational metabolic compound being developed by Novo Nordisk.
It was previously widely referred to by its development name, amycretin.
Zenagamtide is designed as a GLP-1 and amylin receptor co-agonist.
This means researchers aren’t simply examining GLP-1 signalling. They’re investigating what happens when GLP-1 and amylin-related signalling are incorporated within the same molecular approach.
This distinguishes zenagamtide from several other major programmes currently being studied.
Why Was Amycretin Renamed Zenagamtide?
New pharmaceutical compounds frequently begin development under research names or codes before receiving an International Nonproprietary Name.
Amycretin was the name commonly used during the earlier stages of development.
The compound is now known as zenagamtide.
Because much of the earlier scientific literature and online discussion refers to amycretin, both names are likely to continue appearing in searches for some time.
When reading research, it’s therefore useful to understand that amycretin and zenagamtide refer to the same development programme, rather than two unrelated compounds.
What Does GLP-1 Do?
GLP-1 stands for glucagon-like peptide-1.
It is a naturally occurring hormone involved in several aspects of metabolic regulation.
The GLP-1 receptor has become one of the most intensively investigated targets in modern metabolic medicine.
However, researchers increasingly recognise that metabolism involves numerous interacting hormonal pathways.
That has encouraged investigation into combinations involving GLP-1 and other signalling systems.
One of those systems is amylin.
What Is Amylin?
Amylin is a peptide hormone produced by pancreatic beta cells and released alongside insulin.
It participates in several physiological processes associated with metabolic regulation.
Researchers have therefore developed modified versions and analogues of amylin that can be investigated experimentally.
Cagrilintide is one prominent example.
Zenagamtide takes the concept in another direction by incorporating GLP-1 and amylin receptor activity within a single investigational molecule.
Zenagamtide vs Cagrilintide
These compounds are related through their connection to amylin research, but they’re not the same.
Cagrilintide is a long-acting amylin analogue.
Zenagamtide is designed as a GLP-1 and amylin receptor co-agonist.
There is another important distinction.
Cagrilintide is being investigated alongside semaglutide in the combination known as CagriSema.
That strategy combines two separate components:
Cagrilintide + semaglutide
Zenagamtide instead attempts to incorporate activity associated with both pathways into one molecule.
These represent two different approaches to investigating GLP-1 and amylin biology.
Zenagamtide vs Retatrutide
Zenagamtide and retatrutide are another interesting comparison because both illustrate the move towards multi-pathway metabolic research.
Their targets, however, are different.
Zenagamtide: GLP-1 + amylin receptor agonism.
Retatrutide: GIP + GLP-1 + glucagon receptor agonism.
Retatrutide is therefore generally described as a triple agonist, whereas zenagamtide is a GLP-1/amylin co-agonist.
Neither mechanism should automatically be interpreted as superior simply because it involves a particular number of pathways.
Their clinical characteristics have to be established through controlled research.
Oral and Injectable Zenagamtide Research
Another particularly interesting aspect of the programme has been the investigation of different formulations.
Novo Nordisk has investigated both subcutaneous and oral versions of the compound.
This is scientifically important because oral delivery is becoming an increasingly significant research area within metabolic medicine.
Developing peptide-based or peptide-related therapies for oral administration can be challenging because biological molecules may be degraded within the gastrointestinal system and often have limited absorption.
Research into oral formulations therefore represents an important technological challenge as well as a pharmacological one.
What Has Research Found So Far?
Zenagamtide has progressed through clinical development, with Novo Nordisk reporting Phase 2 findings during 2026.
The research has examined metabolic outcomes as well as safety and tolerability.
However, results from an individual clinical trial shouldn’t be interpreted in isolation or used to make direct claims about superiority over other investigational compounds.
Differences in study populations, duration, design, doses and endpoints can make comparisons between separate trials misleading.
The programme is now moving further into late-stage development.
Why Is Zenagamtide Important?
Zenagamtide illustrates an important shift occurring across metabolic research.
The field can broadly be viewed as progressing through several approaches:
Single-receptor agonism
↓
Dual-receptor agonism
↓
Triple-receptor agonism
↓
Combinations and co-agonists involving additional hormonal pathways
Amylin has become particularly important within that final category.
Researchers are now exploring whether incorporating amylin signalling alongside established metabolic pathways can produce useful biological effects.
Zenagamtide is one of the clearest examples of this strategy.
Is Zenagamtide a Peptide?
Zenagamtide is a peptide-based investigational molecule designed to activate GLP-1 and amylin receptors.
However, simply describing a compound as a “peptide” doesn’t explain its biological mechanism.
Different peptides can interact with completely different receptors and physiological systems.
Understanding the actual receptor targets is therefore considerably more informative than relying solely on the peptide label.
Is Zenagamtide Approved?
No.
Zenagamtide remains investigational.
It has not completed the regulatory process required for general medical use.
Clinical research is continuing to establish its efficacy, safety, tolerability and potential role within metabolic medicine.
Why Amylin Is Becoming So Important
Perhaps the bigger story surrounding zenagamtide is the growing importance of amylin itself.
For years, much of the public discussion around metabolic medicines concentrated on GLP-1.
Research is now becoming substantially broader.
Scientists are investigating:
- GLP-1
- GIP
- glucagon
- amylin
- multi-receptor agonists
- hormone combinations
- oral metabolic compounds
Zenagamtide sits directly within this new generation of research.
Rather than replacing GLP-1 research, these programmes are examining what may happen when additional biological pathways are incorporated alongside it.
The Next Stage of Zenagamtide Research
The development of zenagamtide is still ongoing.
Later-stage trials will provide substantially more information than is currently available and will help researchers determine how the GLP-1/amylin co-agonist approach compares with other emerging strategies.
For now, zenagamtide provides another important example of how rapidly metabolic science is moving beyond single-receptor research.
⸻
Research Notice: This article is provided for educational and scientific-information purposes. Zenagamtide (formerly amycretin) remains investigational. Nothing in this article constitutes medical advice, treatment guidance or dosing information.